Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$12.34
+7.4%
$10.03
$5.01
$18.70
$86.63M0.26111,636 shs90,718 shs
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
$0.89
+1.5%
$0.72
$0.49
$2.62
$80.10M1.89202,131 shs86,869 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.46
+4.3%
$1.38
$0.90
$1.96
$17.08M0.5226,692 shs10,579 shs
VolitionRx Limited stock logo
VNRX
VolitionRx
$0.69
+1.0%
$0.71
$0.40
$0.94
$74.03M1.26196,231 shs151,691 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-2.30%-1.96%-11.75%+60.92%+58.48%
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
-2.74%+19.52%+6.38%+27.00%-64.94%
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00%-3.45%-12.50%+23.89%-4.76%
VolitionRx Limited stock logo
VNRX
VolitionRx
+3.15%+5.78%-7.87%+32.10%+0.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.66 of 5 stars
3.44.00.04.73.13.30.6
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
3.7541 of 5 stars
3.64.00.00.03.81.71.3
Synlogic, Inc. stock logo
SYBX
Synlogic
0.5179 of 5 stars
0.03.00.00.00.61.70.6
VolitionRx Limited stock logo
VNRX
VolitionRx
2.206 of 5 stars
3.50.00.00.02.12.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.80
Moderate Buy$21.0070.18% Upside
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
3.17
Buy$5.25487.91% Upside
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00
N/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
3.00
Buy$3.50408.72% Upside

Current Analyst Ratings Breakdown

Latest SYBX, ATRA, VNRX, and CNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/15/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
8/7/2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
8/7/2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
7/17/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
7/9/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
6/26/2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$4.50 ➝ $4.00
6/10/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$3.00
(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$128.94M0.67N/AN/A($4.99) per share-2.47
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
N/AN/AN/AN/A$0.92 per shareN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/A$1.08 per shareN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
$1.32M56.11N/AN/A($0.11) per share-6.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$85.40M-$0.43N/AN/AN/A3.07%-8.34%6.61%N/A
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
-$26.73M-$0.36N/AN/AN/AN/A-38.80%-37.53%11/5/2025 (Estimated)
Synlogic, Inc. stock logo
SYBX
Synlogic
-$23.36M-$2.51N/AN/AN/AN/A-8.09%-5.50%N/A
VolitionRx Limited stock logo
VNRX
VolitionRx
-$35.32M-$0.25N/AN/A-2,321.14%N/A-163.39%N/A

Latest SYBX, ATRA, VNRX, and CNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$0.32$0.19+$0.51$0.19$4.23 million$17.58 million
8/6/2025Q2 2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
-$0.06-$0.09-$0.03-$0.09N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
1.70
1.70
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
N/A
19.09
19.09
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
3.63
3.63
VolitionRx Limited stock logo
VNRX
VolitionRx
N/A
0.22
0.22

Institutional Ownership

CompanyInstitutional Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
14.03%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%
VolitionRx Limited stock logo
VNRX
VolitionRx
8.09%

Insider Ownership

CompanyInsider Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.00%
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
2.80%
Synlogic, Inc. stock logo
SYBX
Synlogic
3.02%
VolitionRx Limited stock logo
VNRX
VolitionRx
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3307.02 million6.74 millionOptionable
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
789.70 million87.19 millionNot Optionable
Synlogic, Inc. stock logo
SYBX
Synlogic
8011.70 million11.35 millionOptionable
VolitionRx Limited stock logo
VNRX
VolitionRx
80107.60 million80.80 millionOptionable

Recent News About These Companies

Q3 Earnings Forecast for VolitionRx Issued By HC Wainwright
Research Analysts Issue Forecasts for VolitionRx Q3 Earnings
HC Wainwright Has Negative Outlook of VolitionRx Q4 Earnings
Equities Analysts Issue Forecasts for VolitionRx Q4 Earnings
Insights into VolitionRX's Upcoming Earnings
VolitionRx Limited (VNRX) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$12.34 +0.85 (+7.40%)
Closing price 04:00 PM Eastern
Extended Trading
$12.39 +0.05 (+0.41%)
As of 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Context Therapeutics stock logo

Context Therapeutics NASDAQ:CNTX

$0.89 +0.01 (+1.48%)
Closing price 04:00 PM Eastern
Extended Trading
$0.88 -0.01 (-1.46%)
As of 06:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.46 +0.06 (+4.29%)
Closing price 04:00 PM Eastern
Extended Trading
$1.46 0.00 (-0.34%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

VolitionRx stock logo

VolitionRx NYSE:VNRX

$0.69 +0.01 (+1.03%)
Closing price 03:59 PM Eastern
Extended Trading
$0.68 0.00 (-0.73%)
As of 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.